Skip to main content
SpringerLink
Log in

Tumors of the Adrenergic System: Imaging and Therapy

  • Chapter
Diseases of the Abdomen and Pelvis 2010–2013

  • 990 Accesses

Abstract

Neuroendocrine tumors (NET) include pheochromocytoma, neuroblastoma, carcinoid, paraganglioma, chemodectoma, medullary thyroid carcinoma, islet cell tumors, gastrinoma, small cell lung cancer, melanoma, and Merkel cell tumor. NET vary considerably in their clinical presentation, location, and histology but share a common embryonic tissue origin, i.e., the neural crest. In addition, all of these tumors express several unique characteristics that may be exploited in the targeting of radiopharmaceuticals for diagnostic as well as therapeutic purposes [1]. The specific targeting of NET may be achieved via the metabolic route (meta-iodo-benzylguanidine, MIBG), through receptor binding (peptides), or immunologically (antibodies).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Hoefnagel CA (1994) Metaiodobenzylguanidine and somatostatin in oncology: role in the management of neural crest tumours. Eur J Nucl Med 21:561–581

    CAS  PubMed  Google Scholar 

  2. Khafagi FA, Shapiro B, Fig LM et al (1989) Labetalol reduces Iodine-131 MIBG uptake by pheochromocytoma and normal tissues. J Nucl Med 30:481–489

    CAS  PubMed  Google Scholar 

  3. Reubi JC (1995) Neuropeptide receptors in health and disease: the molecular basis for in vivo imaging. J Nucl Med 36:1825–1835

    CAS  PubMed  Google Scholar 

  4. Bardiès M, Bardet S, Faivre-Chauvet A et al (1996) Bispecific antibody and Iodine-131-labeled bivalent hapten dosimetry in patients with medullary thyroid or small-cell lung cancer. J Nucl Med 37:1853–1859

    PubMed  Google Scholar 

  5. Goldsmith SJ (2009) Update on nuclear medicine imaging of neuroendocrine tumors. Future Oncol 5:75–84

    Article  CAS  PubMed  Google Scholar 

  6. Troncone L, Rufini V, Montemaggi P et al (1990) The diagnostic and therapeutic utility of radioiodinated metaiodobenzylguanidine (MIBG). 5 years experience. Eur J Nucl Med 16:325–335

    Article  CAS  PubMed  Google Scholar 

  7. Wiseman GA, Pacak K, O’Dorisio MS et al (2009) Usefulness of 123I-MIBG scintigraphy in the evaluation of patients with known or suspected primary or metastatic pheochromocytoma or paraganglioma: results from a prospective multicenter trial. J Nucl Med 50:1448–1454

    Article  CAS  PubMed  Google Scholar 

  8. Hoefnagel CA, De Kraker J (2004) Pediatric tumors. In: Ell PJ and Gambhir SS (eds) Nuclear medicine in clinical diagnosis and treatment, 3rd edition. Churchill Livingstone, Edinburgh, pp 195–206

    Google Scholar 

  9. Leung A, Shapiro B, Hattner R et al (1997) The specificity of radioiodinated MIBG for neural crest tumors in childhood. J Nucl Med 38:1352–1357

    CAS  PubMed  Google Scholar 

  10. Vik TA, Pfluger T, Kadota R et al (2009) (123)I-mIBG scintigraphy in patients with known or suspected neuroblastoma: results from a prospective multicenter trial. Pediatr Blood Cancer 52:784–790

    Article  PubMed  Google Scholar 

  11. Yeh SDJ, Larson SM, Burch L et al (1991) Radioimmunodetection of neuroblastoma with Iodine-131-3F8: correlation with biopsy, Iodine-131-Metaiodo ben zylguanidine and standard diagnostic modalities. J Nucl Med 32:769–776

    CAS  PubMed  Google Scholar 

  12. Hoefnagel CA, Rutgers M, Buitenhuis CKM et al (2001) A comparison of targetting neuroblastoma with mIBG and anti L1-CAM antibody mAB chCE7: therapeutic efficacy in a neuroblastoma xenograft model and imaging of neuroblastoma patients. Eur J Nucl Med 28:359–368

    Article  CAS  PubMed  Google Scholar 

  13. Hoefnagel CA, Delprat CC, Zanin D, van der Schoot JB (1988) New radionuclide tracers for the diagnosis and therapy of medullary thyroid carcinoma. Clin Nucl Med 13:159–165

    Article  CAS  PubMed  Google Scholar 

  14. Hoefnagel CA and Lewington VJ (2004) MIBG therapy. In: Ell PJ and Gambhir SS (eds) Nuclear medicine in clinical diagnosis and treatment, 3rd edn. Churchill Livingstone, Edinburgh, pp 445–457

    Google Scholar 

  15. Troncone L, Galli G (1991) Proceedings International Workshop on The Role of [131I]metaiodobenzylguanidine in the Treatment of Neural Crest Tumors. J Nucl Biol Med 35:177–362

    Google Scholar 

  16. Baulieu J-L, Guilloteau D, Baulieu F et al (1988) Therapeutic effectiveness of Iodine-131 MIBG metastases of a nonsecreting paraganglioma. J Nucl Med 29:2008–2013

    CAS  PubMed  Google Scholar 

  17. Gedik GK, Hoefnagel CA, Bais E, Olmos RA (2008) 131I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 35:725–733

    Article  CAS  PubMed  Google Scholar 

  18. Safford SD, Coleman RE, Gockerman JP et al (2003) Iodine-131 metaiodobenzylguanidine as an effective treatment for malignant pheochromocytoma and paraganglioma. Surgery 134:956–962

    Article  PubMed  Google Scholar 

  19. Hoefnagel CA (1999) Nuclear medicine therapy of neuroblastoma. Q J Nucl Med 43:336–343

    CAS  PubMed  Google Scholar 

  20. Yanik GA, Levine JE, Matthay KK et al (2002) Pilot study of iodine-131 metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma. J Clin Oncol 20:2142–2149

    Article  CAS  PubMed  Google Scholar 

  21. Voûte PA, van der Kleij AJ, de Kraker J et al (1995) Clinical experience with radiation enhancement by hyperbaric oxygen in children with recurrent neuroblastoma stage IV. Eur J Cancer 31A:596–600

    Article  PubMed  Google Scholar 

  22. Hoefnagel CA, de Kraker J, Valdés Olmos RA, Voûte PA (1994) 131I-MIBG as a first-line treatment in high-risk neur-oblastoma patients. Nucl Med Commun 15:712–717

    Article  CAS  PubMed  Google Scholar 

  23. Kraeber-Bodéré F, Bardet S, Hoefnagel CA et al (1999) Radioimmunotherapy in medullary thyroid cancer using bispecific antibody and iodine-131-labeled bivalent hapten: Preliminary results of a phase I/II clinical trial. Clin Cancer Res 5:3190s–3198s

    PubMed  Google Scholar 

  24. Zuetenhorst H, Taal BG, Boot H et al (1999) Longterm palliation in metastatic carcinoid tumours with various applications of meta-idobenzylguanidine: pharmacological MIBG, 131I-labeled MIBG and the combination. Eur J Gastroenterol Hepatol 11:1157–1164

    Article  CAS  PubMed  Google Scholar 

  25. Safford SD, Coleman RE, Gockerman JP et al (2004) Iodine-131 metaiodobenzylguanidine treatment for metastatic carcinoid. Results in 98 patients. Cancer 101:1987–1993

    Article  CAS  PubMed  Google Scholar 

  26. Taal BG, Hoefnagel CA, Valdés Olmos RA et al (1996) Palliative effect of Metaiodobenzylguanidine in metastatic carcinoid tumors. J Clin Oncol 14:1829–1838

    CAS  PubMed  Google Scholar 

  27. Taal BG, Hoefnagel CA, Boot H et al (2000) Improved effect of 131I-MIBG treatment by predosing with non-radiolabeled MIBG in carcinoid patients, and studies in xenografted mice. Ann Oncol 11:1437–1443

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, The Netherlands Cancer Institute, Amsterdam, The Netherlands

    Cornelis A. Hoefnagel

Authors
  1. Cornelis A. Hoefnagel
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Radiology, University Hospital, Zurich, Switzerland

    J. Hodler

  2. Kilchberg/Zurich, Switzerland

    Ch. L. Zollikofer

  3. Nuclear Medicine, University Hospital, Zurich, Switzerland

    G. K. Von Schulthess

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Verlag Italia

About this chapter

Cite this chapter

Hoefnagel, C.A. (2010). Tumors of the Adrenergic System: Imaging and Therapy. In: Hodler, J., Zollikofer, C.L., Von Schulthess, G.K. (eds) Diseases of the Abdomen and Pelvis 2010–2013. Springer, Milano. https://doi.org/10.1007/978-88-470-1637-8_31

Download citation

  • DOI: https://doi.org/10.1007/978-88-470-1637-8_31

  • Publisher Name: Springer, Milano

  • Print ISBN: 978-88-470-1636-1

  • Online ISBN: 978-88-470-1637-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation